← All trials
NCT04729608
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 22, 2021
- Primary completion
- Jul 31, 2023
- Completion date
- Jul 31, 2024
- First posted
- Jan 28, 2021
- Last posted
- Nov 29, 2021
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Aravive BiologicsLead sponsor
- European Network for Gynaecological Oncological TrialCollaborator
- Aravive BiologicsStudy director
- GOG Foundation, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.